

4th April, 2023

To,
The Manager - Corporate Relationship Dept.
BSE Limited
P. J. Towers, Dalal Street
Fort, Mumbai - 400 001

To,
The Manager - Corporate Compliance
National Stock Exchange of India Ltd
Exchange Plaza, Plot No.C-1,
G Block, BKC, Bandra (E),
Mumbai 400 051

Scrip Code: BSE - 524500

Scrip Code: NSE - KILITCH

Sub: Disclosure under Regulation 31(4) of SEBI (Substantial Acquisition of Shares and Takeover) Regulation, 2011

Dear Sir,

Please find enclosed the yearly disclosure under regulation 31(4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulation, 2011, as amended, received from the Promoter & Promoters Group of the Company for the year ended 31st March, 2023, for your kind perusal and Records.

We request you to kindly take the same on record and acknowledge the receipt.

Thanking you,

Yours Faithfully,

For **Kilitch Drugs (India) Limited**

Pushpa Nyoupane
Company Secretary



4th April, 2023

To,
The Manager - Corporate Relationship Dept.
BSE Limited
P. J. Towers, Dalal Street
Fort, Mumbai - 400 001

To,
The Manager - Corporate Compliance
National Stock Exchange of India Ltd
Exchange Plaza, Plot No.C-1,
G Block, BKC, Bandra (E),
Mumbai 400 051

Scrip Code: BSE - 524500

Scrip Code: NSE - KILITCH

Sub: Disclosure under Regulation 31(4) of SEBI (Substantial Acquisition of Shares and Takeover) Regulation, 2011

Dear Sir,


In terms of Regulation 31(4) SEBI (Substantial Acquisition of Shares and Takeover) Regulation, 2011, we hereby declare and confirm that we, along with persons acting in concert, have not made any encumbrance over the shares held by us, directly or indirectly, during the financial year ended March 31, 2023.

Kindly take on record the above information and acknowledge the receipt of the same

Thanking You,

Yours Faithfully,

For on behalf of **all the Promoters and Promoter Group of Kilitch Drugs (India) Limited**



Mukund Mehta
(Managing Director and Promoter)
Date: 4th April, 2023

CC to:

1. Company Secretary – Kilitch Drugs (India) Limited
2. The Audit Committee – Kilitch Drugs (India) Limited